AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26777773 — intervention group
Group type: COMPARATOR
Intervention: Usual care (medication)
Number of subjects: 248
Study 24655729 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 140
Study 24655729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 22553931 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine (6.4 g/day)
Number of subjects: 144
Study 19820079 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smoking
Number of subjects: 2210
Study 19820079 — intervention group
Group type: COMPARATOR
Intervention: Passive household smoke exposure
Number of subjects: 2210
Study 18008242 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine‐pyrimethamine (SP; 250 and 12.5 mg)
Number of subjects: 1189
Study 18008242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1189
Study 16166818 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml wine from one of four different grapes and fermentation processes
Number of subjects: 60
Study 16166818 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 60
Study 14566165 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg melatonin
Number of subjects: 62
Study 14566165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10907623 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg magnesium citrate twice daily for 1 month
Number of subjects: 45
Study 10907623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 45
Study 8876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Gainers Fuel 1000 (GF)
Number of subjects: 28
Study 8876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphagain (P)
Number of subjects: 28
Study 8876343 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (M)
Number of subjects: 28
Study 10147952 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-heart catheterization (RHC)
Number of subjects: 33
Study 10147952 — intervention group
Group type: COMPARATOR
Intervention: No right-heart catheterization (no RHC)
Number of subjects: 33
Study 6208750 — intervention group
Group type: EXPERIMENTAL
Intervention: Infradiaphragmatic irradiation
Number of subjects: 196
Study 6208750 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cis-platinum, bleomycin, and vinblastine)
Number of subjects: 196
Study 6208750 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 196
Study 6208750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus irradiation
Number of subjects: 196
Study 3946806 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 5 micrograms X kg‐1 X h‐1
Number of subjects: 45
Study 3946806 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 10 micrograms X kg‐1 X h‐1
Number of subjects: 45
Study 3946806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 45
Study 30120775 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous FHR monitoring
Number of subjects: 2652
Study 30120775 — intervention group
Group type: COMPARATOR
Intervention: Intermittent FHR monitoring
Number of subjects: 2652
Study 30120775 — intervention group
Group type: EXPERIMENTAL
Intervention: Both monitoring methods
Number of subjects: 2652
Study 28143529 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, computerized patient decision-aid for immunosuppressive drugs
Number of subjects: 0
Study 28143529 — intervention group
Group type: COMPARATOR
Intervention: Standard pamphlet with information about lupus and its treatment
Number of subjects: 0
Study 25932553 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat (2, 5, 7, or 10 mg once daily)
Number of subjects: 72
Study 25932553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25932553 — intervention group
Group type: EXPERIMENTAL
Intervention: Emixustat
Number of subjects: 72
Study 23545911 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release 45 mg oral minocycline
Number of subjects: 0
Study 23545911 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release 45 mg oral minocycline plus 15% azelaic acid
Number of subjects: 0
Study 20503462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupressure intervention with seed embedding for 15 weeks
Number of subjects: 70
Study 20503462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 18226251 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid use
Number of subjects: 35
Study 18226251 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 35
Study 18226251 — intervention group
Group type: COMPARATOR
Intervention: COPD (former smokers)
Number of subjects: 35
Study 16413877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (12.5 mg) and folic acid (50 mug)
Number of subjects: 24076
Study 16413877 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron, folic acid, and zinc
Number of subjects: 24076
Study 16413877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24076
Study 12409968 — intervention group
Group type: EXPERIMENTAL
Intervention: MCG QRS‐T area integrals and QRS‐T angle in magnetic field maps
Number of subjects: 42
Study 12409968 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS‐T integral 16000 fT.s
Number of subjects: 42
Study 12409968 — intervention group
Group type: COMPARATOR
Intervention: Conventional 12-lead electrocardiographic (ECG) LVH indices (Sokolow‐Lyon voltage, Cornell voltage, Cornell voltage duration product)
Number of subjects: 42
Study 9825256 — intervention group
Group type: EXPERIMENTAL
Intervention: New topical therapies
Number of subjects: 200
Study 9825256 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatments that control IOP effectively over time
Number of subjects: 200
Study 7907677 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (prothrombin time ratio 1.3‐1.8, international normalised ratio 2.0‐4.5)
Number of subjects: 1100
Study 7907677 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 1100
Study 7907677 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1100
Study 2811069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg) administered twice daily for five days
Number of subjects: 8
Study 2811069 — intervention group
Group type: COMPARATOR
Intervention: Bumetanide (1 mg, i.v.) administered for the last three days of each period
Number of subjects: 8
Study 2811069 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for five days
Number of subjects: 8
Study 4037 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg terbutaline sulfate (beta‐adrenoceptor stimulating compound)
Number of subjects: 8
Study 4037 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 8
Study 29752828 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes containing 20 mg of THC
Number of subjects: 0
Study 29752828 — intervention group
Group type: COMPARATOR
Intervention: Driving simulation conditions
Number of subjects: 0
Study 27032659 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE (Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education)
Number of subjects: 145
Study 27032659 — intervention group
Group type: COMPARATOR
Intervention: Person-centered treatment planning (Control)
Number of subjects: 145
Study 24365986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac (twice-daily)
Number of subjects: 20
Study 24365986 — intervention group
Group type: EXPERIMENTAL
Intervention: TacMR (once-daily)
Number of subjects: 20
Study 24365986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac (twice-daily) after switching back
Number of subjects: 20
Study 22375890 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet (16% MUFA and 8% SFA)
Number of subjects: 17
Study 22375890 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich diet (16% SFA and 8% MUFA)
Number of subjects: 17
Study 22375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 17
Study 20584695 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-prescribed decoction eliminating herpes combined with recombinant IL-2 and valaciclovir hydrochloride tablets
Number of subjects: 140
Study 20584695 — intervention group
Group type: COMPARATOR
Intervention: Recombinant IL-2 and valaciclovir hydrochloride tablets
Number of subjects: 140
Study 18676527 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of American ginseng extract
Number of subjects: 46
Study 18676527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of American ginseng extract
Number of subjects: 46
Study 18676527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 15811052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybersonic
Number of subjects: 120
Study 15811052 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun 3D Excel
Number of subjects: 120
Study 15811052 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (Elmex super 29)
Number of subjects: 120
Study 12971959 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic therapy (specifics not detailed)
Number of subjects: 314
Study 12971959 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic therapy (control group)
Number of subjects: 314
Study 10395842 — intervention group
Group type: EXPERIMENTAL
Intervention: Canarypox vaccine expressing multiple HIV-1 genes given alone or with rgp120
Number of subjects: 0
Study 10395842 — intervention group
Group type: EXPERIMENTAL
Intervention: Canarypox vaccine expressing multiple HIV-1 genes given with rgp120
Number of subjects: 0
Study 8618110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet-pivoxil (CET, 500 mg BID)
Number of subjects: 24
Study 8618110 — intervention group
Group type: COMPARATOR
Intervention: Cefixime (CFX, 400 mg qD)
Number of subjects: 24
Study 8618110 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (CA, 250 mg BID)
Number of subjects: 24
Study 2405523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (CM) 1 gram IV every 8 hours for 3 doses starting 30 minutes before surgery
Number of subjects: 78
Study 2405523 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (CX) 2 grams IV every 6 hours for 3 doses
Number of subjects: 78
Study 2405523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmetazole (CM)
Number of subjects: 78
Study 2405523 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (CX)
Number of subjects: 78
Study 116287 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 12
Study 29609113 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin/D-mannitol study product
Number of subjects: 25
Study 29609113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without glycyrrhizin/D-mannitol)
Number of subjects: 25
Study 27549811 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed exercise
Number of subjects: 44
Study 27549811 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 44
Study 27549811 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and CBT
Number of subjects: 44
Study 27549811 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 44
Study 24458748 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-space flight skin sensitivity measurement at 250 Hz at the heel for hypersensitive astronauts (n = 6)
Number of subjects: 11
Study 24458748 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-space flight computerized dynamic posturography (CDP) equilibrium (EQ) scores for hypersensitive astronauts (n = 6)
Number of subjects: 11
Study 24458748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-space flight skin sensitivity measurement at 3 and 25 Hz on the great toe
Number of subjects: 11
Study 23110444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen foam dressing
Number of subjects: 120
Study 23110444 — intervention group
Group type: COMPARATOR
Intervention: Comparator foam dressing without ibuprofen
Number of subjects: 120
Study 20504911 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (240 to 320 mg.day(‐1))
Number of subjects: 8
Study 20504911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin B2-type receptor antagonist icatibant (50 mug.kg(‐1))
Number of subjects: 8
Study 20504911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17646507 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid management (median 4250 mL, range 3150-5200 mL)
Number of subjects: 48
Study 17646507 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid management (median 1740 mL, range 1100-2165 mL)
Number of subjects: 48
Study 15810473 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction Vitalizer toothbrush
Number of subjects: 50
Study 15810473 — intervention group
Group type: COMPARATOR
Intervention: Oral-B CrossAction toothbrush
Number of subjects: 50
Study 15810473 — intervention group
Group type: COMPARATOR
Intervention: Oral-B Advantage toothbrush
Number of subjects: 50
Study 15810473 — intervention group
Group type: COMPARATOR
Intervention: Crest SpinBrush Pro brush
Number of subjects: 50
Study 12003176 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte apheresis
Number of subjects: 30
Study 12003176 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 30
Study 10098823 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive behaviorally oriented program for lifestyle change
Number of subjects: 93
Study 10098823 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 8732114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary microwave hyperthermia combined with external irradiation (R + H)
Number of subjects: 125
Study 8732114 — intervention group
Group type: COMPARATOR
Intervention: Radiation (R) alone
Number of subjects: 125
Study 8732114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary microwave hyperthermia with T90 >= 43 degrees C
Number of subjects: 125
Study 1931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 4 micrograms kg‐1
Number of subjects: 20
Study 1931398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 2 micrograms kg‐1
Number of subjects: 20
Study 1931398 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study 6110088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine (3 monthly injections)
Number of subjects: 318
Study 6110088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corresponding injections)
Number of subjects: 318
Study 31924327 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight (BW) protocol (n=245)
Number of subjects: 489
Study 31924327 — intervention group
Group type: COMPARATOR
Intervention: Body surface area (BSA) protocol (n=244)
Number of subjects: 489
Study 31794470 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 0
Study 31794470 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymectomy plus prednisone
Number of subjects: 0
Study 31794470 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 0
Study 27807290 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel scoring system
Number of subjects: 111
Study 27807290 — intervention group
Group type: COMPARATOR
Intervention: Eichenholtz system
Number of subjects: 111
Study 27807290 — intervention group
Group type: COMPARATOR
Intervention: Schon system
Number of subjects: 111
Study 26368296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine granules 1.5 g once daily for 6 months
Number of subjects: 0
Study 26368296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24418672 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper body resistance exercise
Number of subjects: 11
Study 24418672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body resistance exercise
Number of subjects: 11
Study 22245162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench step exercise
Number of subjects: 26
Study 22245162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 20930279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phenserine (10 and 15 mg BID)
Number of subjects: 164
Study 20930279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phenserine (more than 12 weeks)
Number of subjects: 164
Study 20930279 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phenserine (after 12 weeks)
Number of subjects: 164
Study 17389347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindsight group (informed of suicide or homicide occurring after release)
Number of subjects: 235
Study 17389347 — intervention group
Group type: COMPARATOR
Intervention: Control group (withheld outcome information)
Number of subjects: 235
Study 17389347 — intervention group
Group type: EXPERIMENTAL
Intervention: AAPL members
Number of subjects: 235
Study 17389347 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-AAPL members
Number of subjects: 235
Study 16361622 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 85 mg/m2 on day 8 plus gemcitabine 800 mg/m2 on days 1 and 8 (arm A)
Number of subjects: 96
Study 16361622 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 on day 1 plus cisplatin 75 mg/m2 on day 1 (arm B)
Number of subjects: 96
Study 12036812 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lactalbumin diet
Number of subjects: 23
Study 12036812 — intervention group
Group type: COMPARATOR
Intervention: sodium caseinate (control diet)
Number of subjects: 23
Study 10379016 — intervention group
Group type: COMPARATOR
Intervention: Butter-enriched diet (high in saturated fat)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil diet (0.5 g trans fatty acid per 100 g)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiliquid margarine diet (0.5 g trans fatty acid per 100 g)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft margarine diet (7.4 g trans fatty acid per 100 g)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortening diet (9.9 g trans fatty acid per 100 g)
Number of subjects: 36
Study 10379016 — intervention group
Group type: EXPERIMENTAL
Intervention: Stick margarine diet (20.1 g trans fatty acid per 100 g)
Number of subjects: 36
Study 8339102 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 34
Study 2436423 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 11a-hydroxyprogesterone lotion
Number of subjects: 10
Study 2436423 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 10
Study 31721143 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks
Number of subjects: 100
Study 31721143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30728339 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS + LTRA
Number of subjects: 28
Study 30728339 — intervention group
Group type: COMPARATOR
Intervention: ICS
Number of subjects: 28
Study 27266769 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance directive that defaults to comfort care, enabling patients to opt into life-extending care
Number of subjects: 270
Study 27266769 — intervention group
Group type: COMPARATOR
Intervention: Advance directive that defaults to life-extending care, enabling patients to opt out from such care
Number of subjects: 270
Study 27266769 — intervention group
Group type: COMPARATOR
Intervention: Traditional advance directive that requires patients to actively choose their goals of care
Number of subjects: 270
Study 25342408 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided goal-directed fluid therapy
Number of subjects: 56
Study 25342408 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid therapy
Number of subjects: 56
Study 22418065 — intervention group
Group type: EXPERIMENTAL
Intervention: MP29-02 (azelastine and fluticasone propionate)
Number of subjects: 3398
Study 22418065 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 3398
Study 22418065 — intervention group
Group type: COMPARATOR
Intervention: Azelastine
Number of subjects: 3398
Study 22418065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3398
Study 20576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive communication system (ICS) with family meetings within 5 days of ICU admission and weekly thereafter
Number of subjects: 481
Study 20576734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive communication system (ICS)
Number of subjects: 481
Study 20576734 — intervention group
Group type: COMPARATOR
Intervention: Usual care and communication (Control)
Number of subjects: 481
Study 18004131 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB (40 or 60 mg/kg)
Number of subjects: 12
Study 18004131 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.25 mg)
Number of subjects: 12
Study 18004131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.7 g/kg)
Number of subjects: 12
Study 18004131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15617670 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming actions as verbs in citation form
Number of subjects: 0
Study 15617670 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming actions as verbs inflected for third person singular or plural
Number of subjects: 0
Study 15617670 — intervention group
Group type: COMPARATOR
Intervention: Control group (naming actions with unrelated distracters)
Number of subjects: 0
Study 12062456 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100 mg bid)
Number of subjects: 69
Study 12062456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10202741 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17-beta estradiol 50 micrograms/d
Number of subjects: 96
Study 10202741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound 3.32 g/d
Number of subjects: 96